Поиск по репозиторию
Статья
Coronavirus 2019 (COVID 19) was first detected in December 2019 in China. It has become a pandemic. With concern about therapies that may decrease immunity and enhance the severity of an individual's COVID-19 infection, leading to a possibly fatal outcome, use of immunosuppressants has become an important concern. This work focuses on management of various skin diseases individuals lacking immunity to COVID-19 but requiring a systemic immunosuppressant, keeping in view the challenge of the COVID 19 pandemic and that our knowledge of this virus and its effects on the immune system are incomplete including knowledge as to an individual's immunity after COVID-19 infection. © 2020 Wiley Periodicals LLC.
Цитирование
Похожие публикации
Версии
- 1. Version of Record от 2021-04-27
Метаданные
Название журнала
- Dermatologic Therapy
Том
- 33
Выпуск
- 6
Страницы
- -
Ключевые слова
- biological product; cyclophosphamide; dexamethasone; glucocorticoid; immunosuppressive agent; immunosuppressive agent; atopic dermatitis; China; coronavirus disease 2019; dermatology; dermatomyositis; disease control; disease severity; drug efficacy; emergency care; erosion; home quarantine; human; immunosuppressive treatment; myositis; pandemic; pemphigus; pemphigus vulgaris; psoriasis; psoriasis vulgaris; psoriatic arthritis; psoriatic erythroderma; pustular psoriasis; relapse; Review; skin disease; Stevens Johnson syndrome; systemic therapy; toxic epidermal necrolysis; immunology; severity of illness index; skin disease; COVID-19; Humans; Immunosuppressive Agents; Severity of Illness Index; Skin Diseases
Издатель
- Blackwell Publishing Inc.
Тип документа
- Review
Источник
- scopus
